OPKO以7.22亿美元向Labcorp出售BioReference实验室业务 另有最高1.5亿美元或有对价
Miami讯——OPKO Health（纳斯达克：OPK）10月15日宣布，其子公司BioReference Health已与Labcorp（纽交所：LH）签署日期为10月14日的资产购买协议，将旗下临床与解剖病理实验室检测业务出售给Labcorp：交割时现金对价7.22亿美元（可视收入情况调整），另有与4Kscore前列腺癌检测收入挂钩的最高1.5亿美元对价，分最长十年支付。
出售资产包括临床诊断、女性健康、泌尿科和惩教检测业务、80多个患者服务中心，以及已获FDA批准的4Kscore检测（2025年收入2710万美元）。Labcorp预计被收购业务在交割后首年带来约2.5亿美元收入。交易不设融资条件，须通过《哈特-斯科特-罗迪诺法》审查；若未能在2027年4月14日前交割，双方可终止协议；若因特定反垄断情形终止，Labcorp须支付2888万美元终止费。
OPKO董事长兼首席执行官Phillip Frost博士在公告中表示，出售将使公司精简运营、把资源集中于包括Rayaldee在内的生物制药业务。Labcorp执行副总裁兼诊断业务总裁Bryan Vaughn表示，该交易将扩展Labcorp的检测能力。OPKO总部位于佛罗里达州Miami。
OPKO to Sell BioReference Lab Business to Labcorp for $722 Million Plus Up to $150 Million More
MIAMI — OPKO Health (Nasdaq: OPK) announced on October 15 that its subsidiary BioReference Health has entered into an asset purchase agreement dated October 14, 2026 to sell its clinical and anatomic pathology laboratory testing business to Laboratory Corporation of America Holdings (Labcorp, NYSE: LH) for $722 million in cash at closing, subject to revenue-based adjustments, plus up to $150 million over up to ten years tied to revenue from the 4Kscore prostate cancer test.
The sale includes the clinical diagnostics, women's health, urology and corrections testing businesses, more than 80 patient service centers, and the FDA-approved 4Kscore test, which generated $27.1 million of revenue in 2025. Labcorp expects the acquired businesses to generate about $250 million of revenue in the first year after closing. The deal has no financing condition and is subject to HSR clearance; the parties may terminate if it has not closed by April 14, 2027, and Labcorp would pay a $28.88 million termination fee if the deal fails in specified antitrust circumstances.
Phillip Frost, M.D., OPKO's chairman and chief executive, said in the release that the sale streamlines operations and focuses resources on the company's biopharmaceutical business, including Rayaldee. Bryan Vaughn, Labcorp's executive vice president and president of Diagnostics, said the transaction expands Labcorp's testing capabilities. OPKO is headquartered in Miami, Florida.
发布：GSM·美国（发布链接）
图片来源：Labcorp公司官方标志 / Labcorp official logo
GSM Global · 本篇英文版 English edition of this story
